Senti Biosciences, Inc. SNTI 深 滬
已收盤 04-02 16:00:00 美东时间
0.8563
+0.017
+2.07%
華盛通- 最 高0.87
- 今 開0.83
- 成交量 8.61万股
- 最 低 0.82
- 昨 收 0.8389
- 總市值 2666.90万
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 0.7702
- 委 比 -36.62%
- 總股本 3114.45万
- 歷史最高 87.70
- 量 比 0.59
- 振 幅 5.96%
- 歷史最低 0.7702
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.
03-30 19:58
Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.48) by 11.11 percent. This is a 20.9 percent increase over losses of $(0.67) per share
03-27 20:19
Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Evaluating SENTI-202, CD33/FLT3-Targeting Logic Gated CAR NK Cell Therapy, In Patients With R/R AML
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profileCompany planning for rapid advancement of SENTI-202 into R/R AML pivotal
02-11 21:39
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Market-Moving News for December 9th
XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the
2025-12-09 20:21
Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers
2025-12-09 20:17
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6
Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Outperform rating and announces Price Target of $6.
2025-11-21 22:34
Senti Biosciences Q3 EPS $(0.69) Misses $(0.56) Estimate
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.56) by 23.21 percent. This is a 89.06 percent increase over losses of $(6.31) per share
2025-11-14 06:02
